Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

General Anxiety Disorder Clinical Trial

Official title:

A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00233675
• Other study ID #: C6671A/301/AX/US
• Status: Completed
• Phase: Phase 3
• Start date: August 2003

Study information

• Verified date: April 2023
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. primary completion date: February 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years
• Eligibility: Not available at time of registration

Related Conditions & MeSH terms

• Anxiety Disorders
• General Anxiety Disorder

Intervention

Drug:
• GABITRIL (tiagabine hydrochloride; CEP-6671)

Locations

Country	Name	City	State
United States	Claghorn-Lesem Research	Bellaire	Texas
United States	Southwestern Research	Beverly Hills	California
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Social Psychiatry Research Ins	Brooklyn	New York
United States	South East Health Consultants	Charleston	South Carolina
United States	CNS Research Institute	Clementon	New Jersey
United States	Radiant Research Denver	Denver	Colorado
United States	Cunningham Clinical Research	Edwardsville	Illinois
United States	Comprehensive Neuroscience Of	Falls Church	Virginia
United States	University of Connecticut	Farmington	Connecticut
United States	Summit Research Network Farmin	Farmington Hills	Michigan
United States	Clinical Neuroscience Solution	Jacksonville	Florida
United States	Pivotal Research Center	Mesa	Arizona
United States	Fieve Clinical Services, Inc.	New York	New York
United States	Medical and Behavioral	New York	New York
United States	Medical Research Network	New York	New York
United States	Pharmacology Research Institut	Newport Beach	California
United States	Pharmacology Research Institut	Northridge	California
United States	Pacific Clinical Research Medi	Orange	California
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Summit Research Network Inc.	Portland	Oregon
United States	Richard Weisler, MD and Assoc	Raleigh	North Carolina
United States	Radiant Research Salt Lake	Salt Lake City	Utah
United States	Affiliated Research Institute	San Diego	California
United States	Radiant Research San Diego	San Diego	California
United States	Summit Seattle Boren	Seattle	Washington
United States	Carman Research	Smyrna	Georgia
United States	Clinical Neuroscience Solution	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Cephalon

Country where clinical trial is conducted

United States,